Moderna shares get a shot in arm
Digest more
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran;
Moderna Inc. MRNA stock is trading lower after it rallied around 170% on Wednesday on upbeat data from individualized cancer therapy for advanced skin cancer. At a pre-planned interim analysis, Merck & Co Inc.
Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
Zacks Investment Research on MSN
Can Merck's new drugs offer growth cushion ahead of Keytruda LOE?
Merck MRK is increasingly relying on the growing portfolio of newer products, recent acquisitions and pipeline candidates to support long-term growth as it prepares for the eventual loss of exclusivity (“LOE”) of the blockbuster cancer drug Keytruda.
Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak occurred on August 19,
Newsable Asianet News on MSN
Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ for a company facing a major loss of exclusivity in two years.
Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized mRNA therapy intismeran autogene to Keytruda reduced the risk of recurrence and distant spread in patients with resected melanoma,
Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment.
Merck (MRK) is back in focus after announcing that its personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, achieved statistically significant gains in keeping high-risk melanoma from recurring or spreading in a Phase 3 trial.